Oncolys BioPharma Inc.
 

October 20 "Global Licensing Agreement for Investigational HIV Compound (OBP-601) Wins 2011 Deals of DistinctionTM Award"


December 20 Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement For Investigational HIV Compound


October 13 ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG

• February 10 Oncolys BioPharma Inc. Presented A Result of Phase Ia Clinical Study for OBP-601, A Novel Anti-HIV Drug, at 16th CROI Held in Montreal, Canada.

• February 4 Oncolys BioPharma Inc. commenced a repeated dose phase Ib clinical study for OBP-601, a novel anti-HIV drug, in HIV infected patients.

 
• January 21 ONCOLYS BIOPHARMA AND SYSMEX CORPORATON SIGN COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR IN-VITRO CANCER CIRCULATING TUMOR CELL DIAGNOSTIC AGENT


• May 29 ONCOLYS BIOPHARMA DISCLOSED THE INTERIM CLINICAL RESULT OF A PHASE I CLINICAL TRIAL OF TELOMELYSINTM (OBP-301) AT ASCO 2008 (AMERICAN SOCIETY OF CLINICAL ONCOLOGY), IN CHICAGO

• April 15 OBP-601 successfully passed the US FDA IND review process and is ready to initiate Ph-I clinical trial in the United States.

• March 24 Oncolys BioPharma, Inc. Raises $8.2Million (JPY 815,980,000) In Equity Private Placements  

• March 18 Oncolys BioPharma Inc. submitted an IND for OBP-601,a novel anti-HIV drug, to the FDA to gain permission to initiate Ph-Iclinical trial in human.

• March 13 ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG

• March 6 Oncolys BioPharma and Medigen Biotechnology Enters Strategic Alliance and License Agreement to Develop and Commercialize Telomelysin® (OBP-301) for a Potential New Treatment for Solid Tumors


• November 5 Oncolys BioPharma Opens New Research Center in Kobe

• June 21 ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS FORM STRATEGIC ALLIANCE TO DEVELOP RNAi HEPATITIS C DRUG


• November 2 Oncolys BioPharma, Inc. Raises $23.8 Million (JPY 2.6 Billion) In Equity Private Placements

• October 31 Oncolys BioPharma Announces That The First Patient Is in The Phase I Clinical Study of Telomelysin® for Solid Tumors in US

• October 11 Oncolys BioPharma Opened Own Research Center

• August 25 Japan’s First Anti-cancer Adenovirus Is Now GO for Clinical Studies in US

• June 27 Yale Licenses Potential Anti-HIV Agent to Oncolys BioPharma of Japan
Link・・・http://www.yale.edu/opa/newsr/06-06-27-01.all.html

| HOME |
Copyright (c)2004-2005, Oncolys BioPharma Inc. All rights reserved.